Curebound Grants $2 Million to Cancer Research Innovations
Curebound, a philanthropic organization dedicated to cancer research, has awarded eight grants totaling $2 million to innovative oncology-based projects....
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trial Quality Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Curebound, a philanthropic organization dedicated to cancer research, has awarded eight grants totaling $2 million to innovative oncology-based projects....
Epineuron has achieved a significant milestone with the approval of its PeriPulse™ system by Health Canada. This innovative nerve...
In a Phase 1 clinical trial, Metsera’s MET-097 exhibited promising weight loss outcomes, supporting its potential for once-monthly dosing....
LEO Pharma presented data at the 33rd European Academy of Dermatology and Venereology (EADV) Congress on the effectiveness and...
City of Hope, a leading cancer research and treatment institution, has received a $20 million donation from philanthropists Norman...
Genialis, a leader in RNA biomarker development, has announced the launch of Genialis krasID, a groundbreaking biomarker capable of...
Pfizer has voluntarily withdrawn OXBRYTA (voxelotor) from all markets due to an imbalance in vaso-occlusive crises and fatal events...
Merck’s Phase 3 KEYFORM-007 trial tested the efficacy of a fixed-dose combination of favezelimab and pembrolizumab in treating PD-L1-positive...
Japan’s Ministry of Health has approved new indications for KEYTRUDA (pembrolizumab) in treating certain lung and urothelial cancers. KEYTRUDA,...
A groundbreaking medical study, the SuperSaturated Oxygen Comprehensive Observational REgistry (SSCORE), has commenced with enrolling its first patient. This...